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A B S T R A C T
Background: Testosterone has been implicated in suicidality in cross-sectional studies. Stress that coincides with
a suicide attempt may alter androgen levels, so prospective studies are needed to exclude reverse causation. We
aimed to examine the associations of plasma androgens with concurrent and future suicidality, and if present,
whether these associations were mediated by a behavioral trait like reactive aggression.
Methods: Baseline plasma levels of total testosterone, 5α−dihydrotestosterone, and androstenedione were de-
termined with liquid chromatography–tandem mass spectrometry, and dehydroepiandrosterone-sulphate with a
radioimmunoassay. Suicidality was assessed using the Suicidal Ideation Scale at baseline and after 2-, 4-, 6-, and
9-year follow-up. Men and women were analyzed separately, and potential confounders were considered.
Results: Participants (N = 2861; 66.3% women) had a mean age of 42.0 years (range 18–65) and almost half
(46.9%) fulfilled criteria for a major depressive or anxiety disorder. At baseline 13.2% of men and 11.2% of
women reported current suicidal ideation. In participants who were non-suicidal at baseline, slightly more men
than women reported suicidal ideation during follow-up (14.7% vs. 12.5%), whereas the reverse pattern was
observed for suicide attempts (3.6% vs. 4.2%). None of the associations between androgens and current and
future suicidality were significant.
Limitations: Androgens were determined once, which may have been insufficient to predict suicidality over
longer periods.
Discussion: The lack of associations between plasma levels of androgens determined by ‘gold-standard’ labora-
tory methods with suicidality do not support previous cross-sectional and smaller studies in adult men and
women with values within the physiological range.
1. Introduction
Suicidal ideation and suicide attempts (together also known as
suicidality), are a common mental health concern (Nock et al., 2008).
They do not only cause a heavy emotional burden on individuals, but
also on relatives as well as clinicians (Hendin et al., 2000; WHO, 2014).
Approximately twice as many men as women commit suicide
(WHO, 2014). Though reasons for this sex difference remain largely
unknown, one could postulate that differences in the circulating levels
of androgens between the sexes, are implicated in this phenomenon
(Lenz et al., 2019). They are known to alter and to be altered by the
hypothalamic-pituitary-adrenal-axis (HPA-axis), and serotonergic
system, systems that are likely dysregulated in suicidality
(Ludwig et al., 2017; Oyola and Handa, 2017; van Heeringen and
Mann, 2014). Furthermore, these androgens can induce direct genomic
and non-genomic effects by binding to sex steroid receptors in the brain
(McHenry et al., 2014; Schmidt et al., 2000).
Support for a link between androgens and suicidality has come from
cross-sectional studies, mostly conducted in men. One study revealed
that plasma and cerebral spinal fluid (CSF) testosterone levels were
higher in nine male suicide attempters measured two weeks after the
attempt relative to the levels in 12 healthy controls (Stefansson et al.,
2016). Opposite results were reported in two other studies showing
lower plasma testosterone levels in 15 and 80 suicide attempters
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compared to an about equal number of controls (Markianos et al., 2009;
Tripodianakis et al., 2007). However, three other studies with 31–112
suicide attempters found no association (Butterfield et al., 2005; Perez-
Rodriguez et al., 2011; Zhang et al., 2015). Studies in women are more
scarce, but results are similarly inconsistent. A study in 51 women with
bipolar disorder reported that high plasma testosterone was weakly
associated with more suicide attempts, but only in an adjusted analysis
that also included 16 men (Sher et al., 2012). Other studies in 17 and
344 women that measured CSF and/or plasma testosterone found no
significant associations with suicide attempts (Stefansson et al., 2016;
Zhang et al., 2015). No study showed a statistically significant link
between testosterone and suicidal ideation, neither in men nor in
women (Butterfield et al., 2005; Sher et al., 2012, 2014; Zhang et al.,
2015).
The above-described heterogeneity in findings may be related to the
acute stress that accompanies an attempt. Due to the tight coupling
between the hypothalamic-pituitary-gonadal (HPG-) and the HPA-axis,
testosterone levels will be altered after such an event (Oyola and
Handa, 2017). Hence, we cannot conclude from cross-sectional studies
whether the association suggests a mechanism for suicidality or whe-
ther it is a result of experienced stress, thus reflecting reverse causation.
Two studies acknowledged this, and examined whether testosterone
levels predicted suicide attempts during a follow-up of 2.5 and 21 years
(Sher et al., 2014; Stefansson et al., 2016). Higher baseline plasma
testosterone levels predicted for suicide attempts in one, but not in the
other study (Sher et al., 2014; Stefansson et al., 2016). However, the
sample sizes were limited to 51 and 47 participants, and the analyses
were not adjusted for previous attempts nor stratified for sex.
Reactive aggression refers to aggressive behaviour evoked by a
certain situation. It has been hypothesized that besides the suggested
direct effect of testosterone on suicidality, reactive aggression mediates
this association (Lenz et al., 2019). This follows from studies that
showed increased rates of suicidality among those with aggressive traits
(McCloskey and Ammerman, 2018; Turecki and Brent, 2016), and from
studies that showed -though more consistently in other primates than
humans- associations between androgen levels and aggression
(Archer et al., 2004; Carré et al., 2011; Coccaro, 2017). The revised
Leiden Index of Depression Sensitivity (LEIDS-R) measures cognitive
changes that may occur during depressed mood (for the purpose of this
paper, reactive aggression will refer to aggressive cognitive reactivity)
(Solis et al., 2017). As suicidality is especially prevalent among de-
pressed individuals (Bostwick and Pankratz, 2000), this questionnaire
provides the unique opportunity to study whether a phenotype with
more aggressive behavioral traits or cognitive styles mediates the as-
sociation between androgens and suicidality.
The reported inconsistencies and the paucity of large and pro-
spective studies prompted us to examine the role of androgens in sui-
cidality. To accomplish this, androgens were determined by liquid
chromatography–tandem mass spectrometry (XLC–MS/MS) in a large
study (N = 2861) of men and women with depressive and anxiety
disorders and healthy controls who were followed over nine years.
Using this data, we sought to examine the association between an-
drogen levels and a) concurrent suicidal ideation, and b) suicidal
ideation and suicide attempts during nine years of follow-up, and c)




Data were derived from the Netherlands Study of Depression and
Anxiety (NESDA), an ongoing longitudinal observational cohort study
that started in 2004 (Penninx et al., 2008). Current and remitted de-
pressed participants and healthy controls aged 18–65 years were re-
cruited from the Dutch general population (19%), primary health care
(54%) and specialized mental health care (27%). Ethics committees of
participating universities approved the research design. After giving
written informed consent, 2981 participants were included. Exclusion
criteria were a poor comprehension of the Dutch language, and having
a primary clinical diagnosis of psychotic disorder, ob-
sessive–compulsive disorder, bipolar disorder or severe addiction dis-
order. Presence of mood disorders (within the past month) were as-
certained using the Composite International Diagnostic Interview (CIDI
version 2.1) administered by trained researcher assistants
(Wittchen, 1994). Participants were reassessed after 2 (wave 3 [W3]), 4
(W4), 6 (W5), and 9 years (W6). All follow-up assessments were in-
cluded in this study and had high retention rates (the proportion of the
baseline sample participating) of 87.1% (W3), 80.6% (W4), 75.7%
(W5), and 69.4% (W6).
The present study included participants of whom plasma androgens
levels were available (N = 2917). Seventeen participants were ex-
cluded because they were using sex hormones (World Health
Organization Anatomical Therapeutic Chemical [ATC code] G03) or
hormone antagonists (ATC code L02) (World Health Organization
Collaborarting Centre for Drug Statistic, 2007). Another 39 participants
were excluded, as they were pregnant, transgender, had severely
aberrant testosterone levels probably due to a measurement error, or
had missing values on the outcome measure. Altogether, this resulted in
a final sample of 2861 participants at baseline (96.0% of the total
sample). Excluded participants (N = 120) drank less alcohol (percen-
tage that drinks more than one unit a day 19.8% vs. 12.5%, p= 0.046),
and had more often attempted suicide than included participants
(18.8% vs. 15.8%, p = 0.04; see Supplementary Table 1).
2.2. Androgens
Blood was drawn in the morning (mean 08:48 AM ± 0:25 h) after
an overnight fast (success rate 95.6%). Total testosterone, androstene-
dione, and 5α−dihydrotestosterone (5α-DHT) were determined with
XLC–MS/MS at the Clinical Chemistry department of the University
Medical Centre Groningen. In case insufficient biomaterial was avail-
able to obtain 200 uL (15%), samples were pooled. The lower limit of
quantitation was 0.04 nmol/L for total testosterone and androstene-
dione, and 0.12 nmol/L for 5α-DHT. Participants with values below the
detection limit (n = 1 [0.03%] for total testosterone and n = 178
[6.2%] for 5α-DHT) were given values of 0.01 below the lower limit of
quantitation. Dehydroepiandrosterone-sulphate (DHEAS) was de-
termined using ARCHITECT (ABBOTT, Wiesbaden, Germany) a radio-
immunoassay with chemiflex assay protocol. The detection rate of
DHEAS was ≤0.3 μmol/L with a calibration range of 0.00–40.7 μmol/
L. The inter-assay coefficient of variation was estimated as ≤10%.
2.3. Primary outcomes: suicidal ideation and attempts
Suicidal ideation and suicidal attempts at baseline and follow-up
were assessed with the Suicidal Ideation Scale (SSI) (Beck, 1991;
Beck et al., 1979). Suicidal ideation during the last week was de-
termined with the first 5 items. With these items, participants’ attitudes
toward living and dying were examined with questions like ‘Did you
want to live and how strong was this wish?’ and ‘Did you feel the desire
to harm or poison yourself?’. Suicidal ideation was considered present
(i.e., a dichotomous outcome) when any form of ideation, ranging from
death wish to suicide plans or threats, was expressed. Time to suicidal
ideation was determined as the number of years until a participant
reported suicidal ideation using the herein mentioned questionnaire.
Suicidal attempts were assessed with item 6 ‘Have you ever seriously
attempted to commit suicide?’. Time to suicidal attempt was ascer-
tained as the number of years until a participant reported a suicide
attempt during one of the follow-up assessments. When present, the
date was specified and the number of years between baseline and the
suicide attempt could be calculated.
A.E. de Wit, et al. Journal of Affective Disorders 269 (2020) 78–84
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2.4. Secondary outcomes: reactive aggression
Reactive aggression to sad mood was measured with the reactive
aggression subscale of the revised Leiden Index of Depression
Sensitivity (LEIDS-R)(Solis et al., 2017). This questionnaire intents to
measure cognitive changes that may occur during depressed mood.
Participants filling out the LEIDS-R were instructed to recall a situation
when they felt sad and then rate how well they were able to imagine
this situation (i.e. well, somewhat, or not at all). The reactive aggres-
sion subscale contains 6 items like “When I feel bad, I feel more like
breaking things” and “When I feel down, I lose my temper more easily”.
Participants rated the extent to which each statement applied to them
on a 5-point Likert scale (0, not at all; 1, a bit; 2, moderately; 3,
strongly; 4, very strongly). The sum score of these items ranged from 0
to 24 with a higher score indicating stronger reactive aggression. The
LEIDS-R reactive aggression subscale has good psychometric properties
with a Cronbach α of 0.83(Solis et al., 2017).
2.5. Covariates
Age (in years), education (in years), married or with partner (yes/
no), currently smoking (yes/no), alcohol use (≤ or > 7 units a week),
measured Body Mass Index (BMI), and number of treated chronic so-
matic disorders were considered as covariates. In women, the models
were also accounted for the use of oral contraceptives (yes/no).
2.6. Statistical analyses
All analyses were done in strata, separately for men and women.
Baseline characteristics of participants were presented by means± SD,
geometric mean with 95% confidence interval, and frequencies with
percentages, dependent on the type and distribution of the variable.
Missing values on the covariate alcohol use (n = 39; 1.4%) and BMI
(n = 2; 0.0007%) were imputed with the mean. Due to right skewed-
ness, all androgen levels in women, and androstenedione and DHEAS
levels in men, were log transformed. To ease comparability of effect
sizes, levels of androgens were also standardized before the analyses (z-
values).
In the primary analysis, we examined linear and non-linear asso-
ciations of androgen levels with concurrent suicidal ideation using lo-
gistic regressions. Next, we analyzed linear and non-linear association
between androgen levels and future suicidal ideation, and suicide at-
tempts using Cox proportional hazard models. Participants with sui-
cidal ideation (n = 340) or suicidal attempts (n = 328) at baseline
were excluded. Participants who dropped out before the first follow-up
assessment (n = 221) were also excluded for the analyses on suicidal
ideation. Dropouts after 2 years of follow-up were censored. The Cox
proportional hazards assumption was checked with log-minus-log
(LML) curves.
In the secondary analysis, we examined the association between
androgens and reactive aggression. Subsequently, we tested whether
the significant associations in the primary analysis – if any – were
mediated by reactive aggression, using the indirect method by
Preacher and Hayes (2008). This method estimates the total, direct, and
indirect effects of the independent variable on the dependent variable
through the mediator variable.
All analyses were adjusted for the time-independent covariates as
mentioned below the header ‘covariates’. Data were analyzed using IBM
SPSS Statistics (IBM Corp) version 25, using 2-sided tests. As multiple
tests were performed, we calculated an adjusted False Discovery Rate
[FDR] P cut-off value to avoid the inflation of false-positive findings. A
P-value of <0.0005 was considered statistically significant.
3. Results
Data of 965 men and 1896 women with an age range from 18 to 65
years were included in the analyses. Both men and women were slightly
overweight on average (mean BMI 26.2 ± 4.5 and 25.3 ± 5.2), and
41.8% and 37.0% were smokers, respectively. Almost half of the sample
suffered from either a major depressive or an anxiety disorder in the
preceding month (46.9%), and 99 men (10.3%) and 229 women
(12.1%) had had a preceding suicide attempt. Men had almost 20 times
higher total testosterone levels than women (geometric mean total
testosterone 15.6; 95%CI, 14.6 to 16.6, vs., 0.79; 95%CI, 0.04 to 1.80;
respectively). See also Table 1.
3.1. Suicidal ideation and suicide attempts
As shown in Table 2, about similar rates of men and women ex-
perienced suicidal ideation (13.2% and 11.2%, respectively) at base-
line. Higher levels of androstenedione were associated with increased
odds of suicidal ideation in men (crude standardized odds ratio (OR),
1.42; 95%CI, 1.17–1.72; p = 0.0004), but not after consideration of
covariates (adjusted standardized OR, 1.31; 95%CI, 1.06–1.62;
p = 0.01). None of the other androgens was associated with suicidal
ideation in men or women at baseline. See also Figure 1. Slightly more
men than women reported suicidal ideation during follow-up (113 /
769 [14.7%] compared to 192 / 1531 [12.5%]), whereas the reverse
was observed for suicidal attempts (29 / 866 [3.3%] compared to 64 /
1667 [3.8%]). As shown in Table 3, androgen levels were neither linear
nor non-linearly associated with future suicidal ideation or suicide at-
tempts in men nor in women.
3.2. Reactive aggression
We examined the association of androgens with reactive aggression.
Only higher levels of androstenedione in women was associated more
reactive aggression (crude standardized β, 0.362, 95%CI
[0.166–0.559], p= 0.0003), but not after the adjustment for covariates
(adjusted standardized β, 0.012, 95%CI [−0.219 to −0.243],
Table 1
Characteristics at baseline of the study samples of 2861 men and women
Men Women
n = 965 n = 1896
Age, mean (SD), y 43.6 ± 12.9 41.1 ± 13.1
Education, mean (SD), y 12.1 ± 3.3 12.2 ± 3.3
Married or with partner, no. (%) 675 (69.9) 1306 (68.9)
BMI, mean (SD) 26.2 ± 4.5 25.3 ± 5.2
No. smoking, no. (%) 403 (41.8) 702 (37.0)
No. alcohol intake >1 unit a day, no. (%) 307 (31.8) 262 (13.8)
Treated chronic diseases, geo. mean
(95%CI)
0.5 (0.0–1.5) 0.4 (0.0–1.4)
No. oral contraceptive use, no. (%) – 508 (26.8)
No. antidepressant use, no. (%) 238 (24.7) 498 (26.3)
No. MDD or anxiety disorder past month,
no. (%)
453 (46.9) 889 (46.9)
No. suicide ideation in preceding week,
no. (%)
127 (13.1) 213 (11.2)
No. suicide attempt in past, no. (%) 99 (10.3) 229 (12.1)
Reactive aggression, geo. mean (95%CI) 3.8 (2.8–4.8) 3.4 (2.4–4.4)
Predictors - Androgenic features
Total testosterone (nmol/L), geo. mean
(95%CI)
15.6 (14.6–16.6) 0.79 (0.04–1.80)
5α-DHT (nmol/L), geo. mean (95%CI) 1.5 (0.5–2.5) 0.36 (0.12–1.36)
Androstenedione (nmol/L), geo. mean
(95%CI)
3.7 (2.7–4.7) 3.3 (2.3–4.3)
DHEAS (µmol/L), geo. mean (95%CI) 7.2 (6.2–8.2) 4.7 (3.7–5.7)
Abbreviations: 5α-DHT, 5α dihydrotestosterone; BMI, body mass index (cal-
culated as weight in kilograms divided by height in meters squared); DHEAS,
dehydroepiandrosterone-sulphate; MDD, Major Depressive Disorder.
To convert nmol/L to ng/dl for total testosterone, 5α-DHT, and androstene-
dione multiply by 28.84, 29.07, and 28.64, respectively. To convert pmol/L to
pg/ml for free testosterone divide by 3.47. To convert µmol/L to µg/dl for
DHEAS, multiply by 36.85.
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p = 0.92). See Supplementary Table 2. As none of the associations in
the primary analyses was significant, no mediation analyses with re-
active aggression was performed.
4. Discussion
In this large study among 965 men and 1896 women whose plasma
androgen levels were measured with the best available laboratory
methods, we could not demonstrate significant associations between
plasma levels of androgens with current as well as suicidal ideation or
suicide attempts during follow-up. Therefore, our results challenge
findings from previous studies that plasma androgen levels might be a
viable biomarker of suicidality.
Our analyses focused on associations of plasma androgen levels at
baseline with future suicidal ideation and suicide attempts during
follow-up, as our study was founded on the notion that acute stress that
is experienced by the suicide attempter may increase androgen levels
whereas chronic stress may decrease androgen levels. Hence, this might
explain why we cannot confirm the either positive or negative asso-
ciations between androgens and suicidality that were demonstrated in
previous smaller studies that examined androgen levels directly after a
suicide attempt (Butterfield et al., 2005; Markianos et al., 2009; Perez-
Rodriguez et al., 2011; Roland et al., 1986; Sher et al., 2012;
Stefansson et al., 2016; Tripodianakis et al., 2007; Zhang et al., 2015).
These studies also rarely considered confounders in their analyses and
used less reliable methods than XLC–MS/MS to determine androgen
levels. As a consequence, this might have led to overestimation of true
effect sizes. However, an alternative explanation for the discrepancies
between our results and that of others might be lying in differences in
study population regarding psychiatric diagnoses. We examined parti-
cipants with depression and anxiety, and healthy controls, while pre-
vious significant positive associations were derived from patients with
schizophrenia (Markianos et al., 2009; Tripodianakis et al., 2007), and
significant negative associations from patients with bipolar disorder
(Sher et al., 2012, 2014). Nevertheless, since this study included the
largest sample of men and women so far, the absence of significant
associations suggests that these are –if present at all– of weak strength
and likely not clinically meaningful in a population of depressed and
anxious patients. Finally, the positive findings in smaller previous stu-
dies may be false positive findings or the effect of publication bias.
Studying testosterone during windows of development in which it may
also cause permanent effects on cerebral functioning like antenatal or
during puberty, may be an intriguing alternative direction (Lenz et al.,
Table 2
Associations between baseline plasma androgen levels and concurrent suicidal
ideation in men and women.
Current suicidal ideation
Crude Adjusteda
OR (95% CI) Pb OR (95% CI) Pb
Men
No. events (%) 127 / 965 (13.2)
Total testosterone 1.01 (0.84–1.22) .88 0.95 (0.76–1.17) .60
5α-DHT 0.97 (0.81–1.18) .78 0.92 (0.75–1.13) .42
Androstenedione 1.42 (1.17–1.72) <.0004 1.31 (1.06–1.62) .01
DHEAS 1.07 (0.88–1.29) .50 1.11 (0.87–1.41) .39
Total testosterone 0.91 (0.74–1.11) .33 0.81 (0.64–1.01) .06
Total testosterone2,c 1.21 (1.02–1.44) .03 1.29 (1.08–1.54) .01
5α-DHT 093 (0.75–1.15) .49 0.86 (0.68–1.08) .20
5α-DHT2,c 1.04 (0.95–1.14) .35 1.06 (0.96–1.16) .23
Androstenedione 1.44 (1.17–1.78) .001 1.34 (1.07–1.69) .01
Androstenedione2,c 0.97 (0.85–1.11) .66 0.95 (0.83–1.09) .45
DHEAS 1.01 (0.81–1.26) .92 1.01 (0.81–1.26) .92
DHEAS2,c 0.88 (0.75–1.03) .10 0.88 (0.75–1.03) .10
Women
No. events (%) 213 / 1896 (11.2)
Total testosterone 1.15 (0.99–1.33) .07 1.07 (0.92–1.25) .40
5α-DHT 1.13 (0.98–1.30) .11 1.05 (0.89–1.24) .54
Androstenedione 1.22 (1.06–1.42) .01 1.14 (0.95–1.36) .16
DHEAS 1.08 (0.93–1.25) .33 0.96 (0.81–1.15) .67
Total testosterone 1.18 (1.02–1.35) .02 1.10 (0.94–1.28) .23
Total testosterone2,c 1.13 (1.00–1.28) .05 1.11 (0.98–1.26) .10
5α-DHT 1.12 (0.98–1.28) .09 1.04 (0.89–1.22) .59
5α-DHT2,c 1.19 (1.07–1.34) .002 1.19 (1.06–1.34) .003
Androstenedione 1.25 (1.08–1.44) .002 1.17 (0.98–1.39) .09
Androstenedione2,c 1.08 (1.00–1.16) .06 1.06 (0.97–1.14) .20
DHEAS 1.13 (0.97–1.31) .13 0.99 (0.82–1.20) .93
DHEAS2,c 1.06 (0.98–1.15) .14 1.03 (0.95–1.12) .45
Abbreviations: 5α-DHT, 5α dihydrotestosterone; DHEAS, dehydroepian-
drosterone-sulphate; MDD, Major Depressive Disorder; OR, odds ratio.
To convert nmol/L to ng/dl for total testosterone, 5α-DHT, and androstene-
dione multiply by 28.84, 29.07, and 28.64, respectively. To convert pmol/L to
pg/ml for free testosterone divide by 3.47. To convert µmol/L to µg/dl for
DHEAS, multiply by 36.85.
a Adjusted for age, education, married or with partner, BMI, smoking, al-
cohol use, and number of treated chronic diseases, (and in women also for oral
contraceptive use).
b Based on logistic regression analysis.
c Androgen level is squared to examine non-linear relationship with current
suicidal ideation.
Fig. 1. Percentage of participants with suicidal ideation in the last week according to 7 septiles (i.e., quantiles that divided an ordered sample population into seven
equally numerous subsets) with their mean levels of plasma androgens in 965 men and 1896 women. Abbreviations: DHT, 5α dihydrotestosterone; DHEAS, de-
hydroepiandrosterone-sulphate. To convert nmol/L to ng/dL for total testosterone, 5α-DHT, and androstenedione multiply by 28.84, 29.07, and 28.64, respectively.
To convert pmol/L to pg/ml for free testosterone divide by 3.47. To convert µmol/L to µg/dl for DHEAS, multiply by 36.85. Vertical error bars represent standard
errors of the mean (SE), and horizontal error bars represent 95% CI of the mean of each septile. A second order regression line was fitted.
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2019). Indirect measures of intra-uterine androgen exposure like
second-to-fourth finger length (2D:4D), birth weight and maternal an-
drogen levels, and thus masculinization of the brain, have been asso-
ciated with increased risk of suicide completion during adulthood
(Lenz et al., 2019). Future studies could also look into androgen re-
ceptor CAG trinucleotide repeats rather than plasma levels, as those
better reflect androgen sensitivity (Mobasseri et al., 2018).
We also observed no association between levels of androgens and
reactive aggression after the consideration of important covariates.
Higher levels of aggressiveness have mostly been reported as a side
effect of anabolic androgenic steroid abuse in men and women
(Gruber and Pope, 2000; Onakomaiya and Henderson, 2016;
Strauss et al., 1985), but those concerned supraphysiological 5α-DHT
levels and might therefore not be comparable to the physiological levels
in our cohort of men and natural cycling women. Otherwise, a recent
randomized controlled trial revealed that testosterone could rapidly
potentiate aggressive behaviour, but only among men with dominant or
impulsive personality styles (Carre et al., 2017). Also, men who re-
ceived testosterone were more likely to pay money to punish proposers
who made unfair offers as well as to reward proposers who made fair
offers in the ultimatum game (Dreher et al., 2016). Apparently, tes-
tosterone may evoke both prosocial and antisocial (e.g. aggressive)
aspects depending on the context. Yet, these time- and situation de-
pending differences were not considered in this study which might
explain the lack of associations.
Strengths of this study include the examination of the largest sample
of men and women up to date who were followed over prolonged
periods of time with rigorously assessment of their phenotype with
well-validated questionnaires (Beck et al., 1979; Van der Does, 2002).
Previous studies were smaller, and included up to 490 participants in
cross-sectional analyses (Zhang et al., 2015) and 51 participants in
prospective analyses (Sher et al., 2014). Also, we present the first study
that reliably measured testosterone in women as androgens were de-
termined by the ‘golden-standard’ XLC–MS/MS method. Immunoassays
were less reliable when measuring the low testosterone (<5.0 nmol/L)
levels that are typically present in women due to cross reactivity with
other hormones (Kushnir et al., 2010). Finally, we were able to adjust
for a wide variety of confounders that are important in the potential
association between testosterone and suicidality. Nevertheless, this
study has some limitations. Suicidality was assessed with a 5 item scale
and may wax and wane over time. Therefore, it may have been un-
detected due to the relatively large time intervals between follow-up
assessments in our study. However, if strong associations would exist,
those would resist the long timespan that were present in the long-
itudinal analyses. Also, single measurements may have been insufficient
to predict suicidality over longer periods of time. Yet, levels of testos-
terone, 5α-DHT and androstenedione tend to only slightly decrease
over time in women, and be even stable after menopause (Burger et al.,
2000; Davison et al., 2005; Elmlinger et al., 2005; Rothman et al.,
2011). This decrease is most pronounced in women in their third
decade (Davison et al., 2005), but this age category was only presented
by 23% of our cohort. In middle aged men, a slow aging-related decline
in total testosterone levels of 0.3–1.8% annually, is seen
(Kaufman et al., 2019). Moreover, 5α-DHT levels tend to be stable in
men until the age of 65, like the age range that was included this study
(Handelsman et al., 2015). Likewise, reported intraclass correlation
Table 3
Associations between baseline plasma androgen levels and future suicidal ideation and suicide attempts over 9 years in men and women.
Future suicidal ideation Future suicide attempt
Crude Adjusteda Crude Adjusteda
HR (95% CI) Pb HR (95% CI) Pb HR (95% CI) Pb HR (95% CI) Pb
Men
No. events (%) 113 / 769 (14.7) 29 / 866 (3.3)
Total testosterone 0.87 (0.71–1.06) .17 0.85 (0.68–1.06) .15 1.01 (0.69–1.46) .97 1.02 (0.67–1.55) .94
5α-DHT 0.87 (0.71–1.06) .16 0.86 (0.69–1.06) .16 0.88 (0.60–1.30) .53 0.85 (0.55–1.30) .45
Androstenedione 1.04 (0.87–1.26) .65 1.07 (0.89–1.30) .47 1.13 (0.79–1.62) .52 1.20 (0.82–1.75) .36
DHEAS 0.98 (0.82–1.17) .79 1.13 (0.90–1.41) .28 0.91 (0.64–1.29) .60 1.08 (0.70–1.66) .73
Total testosterone 0.85 (0.69–1.05) .13 0.82 (0.66–1.03) .09 1.02 (0.67–1.57) .91 1.02 (0.64–1.62) .94
Total testosterone2,c 1.08 (0.83–1.40) .58 1.12 (0.785–1.47) .43 0.96 (0.55–1.66) .87 1.00 (0.57–1.76) 1.00
5α-DHT 0.82 (0.66–1.00) .05 0.80 (0.64–0.99) .04 0.96 (0.59–1.57) .87 0.92 (0.55–1.55) .76
5α-DHT2,c 1.07 (0.99–1.16) .11 1.08 (0.99–1.17) .08 0.78 (0.50–1.21) .27 0.78 (0.50–1.22) .27
Androstenedione 1.06 (0.89–1.26) .55 1.08 (0.89–1.31) .45 1.12 (0.79–1.59) .52 1.20 (0.82–1.75) .36
Androstenedione2,c 1.05 (0.95–1.15) .38 1.01 (0.92–1.12) .81 1.03 (0.84–1.26) .77 1.00 (0.82–1.22) .98
DHEAS 1.03 (0.86–1.25) .75 1.23 (0.97–1.55) .09 0.85 (0.56–1.31) .46 0.99 (0.58–1.66) .95
DHEAS2,c 1.07 (0.97–1.18) .18 1.08 (0.98–1.19) .12 0.92 (0.70–1.20) .52 0.91 (0.70–1.19) .50
Women
No. events (%) 192 / 1531 (12.5) 64 / 1667 (3.8)
Total testosterone 0.92 (0.80–1.06) .27 0.96 (0.83–1.11) .57 1.09 (0.84–1.40) .52 0.99 (0.75–1.29) .92
5α-DHT 0.93 (0.80–1.07) .30 0.99 (0.84–1.17) .94 1.29 (1.00–1.66) .05 1.24 (0.93–1.64) .14
Androstenedione 0.97 (0.84–1.12) .67 1.02 (0.87–1.20) .82 1.14 (0.88–1.47) .33 1.00 (0.74–1.35) .99
DHEAS 0.83 (0.73–0.95) .005 0.87 (0.75–1.02) .09 0.99 (0.77–1.27) .92 0.89 (0.66–1.20) .43
Total testosterone 0.94 (0.81–1.09) .42 0.96 (0.82–1.12) .61 1.08 (0.84–1.41) .55 0.98 (0.74–1.30) .88
Total testosterone2,c 1.04 (0.93–1.17) .51 1.00 (0.89–1.12) 1.00 0.96 (0.69–1.34) .82 0.94 (0.67–1.32) .74
5α-DHT 0.93 (0.80–1.07) .31 0.99 (0.84–1.17) .89 1.27 (0.99–1.63) .06 1.22 (0.92–1.62) .16
5α-DHT2,c 1.00 (0.88–1.14) 1.00 0.97 (0.85–1.11) .68 1.05 (0.86–1.30) .62 1.04 (0.85–1.27) .72
Androstenedione 1.03 (0.89–1.19) .69 1.07 (0.90–1.28) .45 1.17 (0.93–1.49) .18 1.04 (0.77–1.39) .81
Androstenedione2,c 1.07 (1.01–1.14) .02 1.04 (0.98–1.11) .21 1.10 (0.98–1.23) .11 1.08 (0.95–1.22) .27
DHEAS 0.88 (0.75–1.03) .10 0.89 (0.74–1.08) .25 1.04 (0.80–1.35) .76 0.94 (0.68–1.28) .68
DHEAS2,c 1.04 (0.97–1.12) .28 1.01 (0.94–1.09) .72 1.07 (0.93–1.22) .35 1.06 (0.92–1.22) .43
Abbreviations: 5α-DHT, 5α dihydrotestosterone; DHEAS, dehydroepiandrosterone-sulphate; HR, hazard ratio; MDD, Major Depressive Disorder.
To convert nmol/L to ng/dl for total testosterone, 5α-DHT, and androstenedione multiply by 28.84, 29.07, and 28.64, respectively. To convert pmol/L to pg/ml for
free testosterone divide by 3.47. To convert µmol/L to µg/dl for DHEAS, multiply by 36.85.
a Adjusted for age, education, married or with partner, BMI, smoking, alcohol use, and number of treated chronic diseases, (and in women also for oral con-
traceptive use).
b Based on cox regression analysis.
c Androgen level is squared to examine non-linear relationship with current suicidal ideation.
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coefficients for testosterone, 5α-DHT and DHEAS are good, ranging
from 0.74 to 0.97, depending on the time between measurements (4
weeks to 5 years) and method used (radio immune assay or LC/MS–MS)
(Cauley et al., 1991; Hsing et al., 2007; Jones et al., 2014). Altogether,
this suggests that a single measure may be reliable for ranking men and
women according to their androgen level for epidemiologic research.
Furthermore, we were not able to account for recent perceived stress
levels, which may be interesting since the HPA-axis and HPG-axis are
known to be coupled (Oyola and Handa, 2017). Finally, we were not
able to study completed attempts. Hence, our results are limited to the
notion of the role of androgens in suicidal ideation and non-lethal at-
tempts.
In conclusion, this study, that followed a large sample of partici-
pants over nine years, showed the absence of significant associations
between plasma androgens and suicidality. Thus, our results do not
support findings from previous cross-sectional and smaller studies on
the role of plasma androgens in suicidality in adult men and women
with values within the physiological range.
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